Crystalline base of trans1-((1R,3S)-6-chloro-3-phenylindan-1-yl) -3,3-dimethylpiperazine

Details for Australian Patent Application No. 2006215957 (hide)

International Classifications

Event Publications

30 August 2007 PCT application entered the National Phase

PCT publication WO2006/086986 Priority application(s): WO2006/086986

29 September 2011 Application Accepted

Published as AU-B-2006215957

15 December 2011 Application for Amendment

The nature of the amendment is: Amend the priority details to read PA200500239 16 Feb 2005 DK. Address for service in Australia - Spruson & Ferguson Level 35 St Martins Tower 31 Market Street Sydney NSW 2000

12 April 2012 Amendment Made

The nature of the amendment is: Amend the priority details to read PA200500239 16 Feb 2005 DK 2006236489 ImmunoGen, Inc. The nature of the amendment is as shown in the statement(s) filed 16 Sep 2011

12 April 2012 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.